Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Experts say that getting infected with measles can pose serious health risks for people that they wouldn’t face if they were vaccinated ...

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

Somewhere deep in my mind, the guilt starts to build as I know this will only make things infinitely worse in the long run.

An expert discusses how the clinical presentations of atopic dermatitis (AD) vary across different patient populations and the challenges these variations pose in diagnosis.

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

A recent study found First Nations Australians were twice as likely to present to an emergency department with asthma or ...

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...